Bibliografia atualizada em fatores prognósticos em câncer de mama.
Autor: Roberto Arcuri | Publicado: 2016-11-29T12:22:00-08:00

1.
Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Abubakar, Mustapha; Orr, Nick; Daley, Frances; Coulson, Penny; Ali, H Raza; Blows, Fiona; Benitez, Javier; Milne, Roger;Brenner, Herman; Stegmaier, Christa; Mannermaa, Arto; Chang-Claude, Jenny; Rudolph, Anja; Sinn, Peter; Couch, Fergus J; Devilee, Peter; Tollenaar, Rob A E M; Seynaeve, Caroline; Figueroa, Jonine; Sherman, Mark E; Lissowska, Jolanta; Hewitt, Stephen; Eccles, Diana; Hooning, Maartje J; Hollestelle, Antoinette; Martens, John W M; van Deurzen, Carolien H M; Investigators, kConFab; Bolla, Manjeet K; Wang, Qin; Jones, Michael; Schoemaker, Minouk; Wesseling, Jelle; van Leeuwen, Flora E; Van 't Veer, Laura; Easton, Douglas; Swerdlow, Anthony J; Dowsett, Mitch; Pharoah, Paul D;Schmidt, Marjanka K; Garcia-Closas, Montserrat.
Breast Cancer Res; 18(1): 104, 2016 Oct 18.
2.
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer.
Dai, Meiou; Zhang, Chenjing; Ali, Ayad; Hong, Xinyuan; Tian, Jun; Lo, Chieh; Fils-Aimé, Nadège; Burgos, Sergio A; Ali, Suhad; Lebrun, Jean-Jacques.
Sci Rep; 6: 35383, 2016 Oct 19.
3.
The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?
Jerzak, Katarzyna J; Pritchard, Kathleen I.
Eur J Cancer; 68: 173-175, 2016 Oct 18.
4.
Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.
Hrebien, Sarah; O'Leary, Ben; Beaney, Matthew; Schiavon, Gaia; Fribbens, Charlotte; Bhambra, Amarjit; Johnson, Richard; Garcia-Murillas, Isaac; Turner, Nicholas.
PLoS One; 11(10): e0165023, 2016.
5.
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger, Anna; Malmström, Per; Bendahl, Pär-Ola; Elston, Christopher W; Falck, Anna-Karin; Forsare, Carina; Grabau, Dorthe; Rydén, Lisa; Stål, Olle; Fernö, Mårten.
Acta Oncol; : 1-7, 2016 Oct 20.
6.
Prognostic Value of E-Cadherin and ß-Catenin in Triple-Negative Breast Cancer.
Shen, Tiansheng; Zhang, Kui; Siegal, Gene P; Wei, Shi.
Am J Clin Pathol; 2016 Oct 25.
7.
Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.
Rakha, Emad A; Agarwal, Devika; Green, Andrew R; Ashankyty, Ibraheem; Ellis, Ian O; Ball, Graham; Alaskandarany, Mohammed A.
Histopathology; 2016 Oct 26.
8.
Biomarker discovery to improve prediction of breast cancer survival: using gene expression profiling, meta-analysis, and tissue validation.
Meng, Liwei; Xu, Yingchun; Xu, Chaoyang; Zhang, Wei.
Onco Targets Ther; 9: 6177-6185, 2016.
9.
Current advances in biomarkers for targeted therapy in triple-negative breast cancer.
Fleisher, Brett; Clarke, Charlotte; Ait-Oudhia, Sihem.
Breast Cancer (Dove Med Press); 8: 183-197, 2016.
10.
Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.
Furrer, Daniela; Lemieux, Julie; Côté, Marc-André; Provencher, Louise; Laflamme, Christian; Barabé, Frédéric; Jacob, Simon; Michaud, Annick; Diorio, Caroline.
Breast; 30: 191-196, 2016 Oct 24.
11.
The analytical validation of the Oncotype DX Recurrence Score assay.
Baehner, Frederick L.
Ecancermedicalscience; 10: 675, 2016.
12.
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi, Misun; Park, Yeon Hee; Ahn, Jin Seok; Im, Young-Hyuck; Nam, Seok Jin; Cho, Soo Youn; Cho, Eun Yoon.
Breast Cancer Res Treat; 2016 Oct 11.
13.
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije, Nick; Onstenk, Wendy; Kraan, Jaco; Sieuwerts, Anieta M; Hamberg, Paul; Dirix, Luc Y; Brouwer, Anja; de Jongh, Felix E; Jager, Agnes; Seynaeve, Caroline M; Van, Ngoc M; Foekens, John A; Martens, John W M; Sleijfer, Stefan.
Neoplasia; 18(11): 647-653, 2016 Oct 17.
14.
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.
Ribatti, Domenico; Nico, Beatrice; Ruggieri, Simona; Tamma, Roberto; Simone, Giovanni; Mangia, Anita.
Transl Oncol; 9(5): 453-457, 2016 Oct.
Artigo em ENG | MEDLINE | ID: mdl-27751350
15.
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
Bae, Sang Byung; Cho, Hyun Deuk; Oh, Mee-Hye; Lee, Ji-Hye; Jang, Si-Hyong; Hong, Soon Auck; Cho, Junhun; Kim, Sung Yong; Han, Sun Wook; Lee, Jong Eun; Kim, Han Jo; Lee, Hyun Ju.
J Breast Cancer; 19(3): 242-251, 2016 Sep.
16.
BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.
Eom, Yong Hwa; Kim, Hyung Suk; Lee, Ahwon; Song, Byung Joo; Chae, Byung Joo.
J Breast Cancer; 19(3): 252-260, 2016 Sep.
17.
Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis.
Shin, Hee-Chul; Han, Wonshik; Moon, Hyeong-Gon; Park, In-Ae; Noh, Dong-Young.
J Breast Cancer; 19(3): 268-274, 2016 Sep.
18.
Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.
Feng, Xiaolan; Li, Haocheng; Kornaga, Elizabeth N; Dean, Michelle; Lees-Miller, Susan P; Riabowol, Karl; Magliocco, Anthony M; Morris, Don; Watson, Peter H; Enwere, Emeka K; Bebb, Gwyn; Paterson, Alexander.
Oncotarget; 2016 Oct 12.
19.
Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal, Jalal; Nafissi, Nahid; Akbari, Mohammad Esmaeil; Mahjub, Hossein; Esmailnasab, Nader; Babaee, Ebrahim.
Arch Iran Med; 19(10): 680-686, 2016 Oct.
20.
Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.
Criscitiello, Carmen; Esposito, Angela; Trapani, Dario; Curigliano, Giuseppe.
Cancer Treat Rev; 50: 205-207, 2016 Oct 6.
21.
Low expression of miR-409-3p is a prognostic marker for breast cancer.
Cao, G-H; Sun, X-L; Wu, F; Chen, W-F; Li, J-Q; Hu, W-C.
Eur Rev Med Pharmacol Sci; 20(18): 3825-3829, 2016 Sep.
22.
Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.
Wang, Jue; Yin, Jun; Yang, Qing; Ding, Feng; Chen, Xiao; Li, Bingjie; Tian, Xingsong.
Oncotarget; 2016 Oct 5.
23.
Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Sahin, Sevinç; Isik Gönül, Ipek; Çakir, Asli; Seçkin, Selda; Uluoglu, Ömer.
Int J Surg Pathol; 24(7): 607-13, 2016 Oct.
24.
ß1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer.
Yin, Hsin-Ling; Wu, Chun-Chieh; Lin, Chih-Hung; Chai, Chee-Yin; Hou, Ming-Feng; Chang, Shu-Jyuan; Tsai, Hung-Pei;Hung, Wen-Chun; Pan, Mei-Ren; Luo, Chi-Wen.
Int J Mol Sci; 17(9)2016.
25.
Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany, Mohammad A; Abduljabbar, Rezvan; Ashankyty, Ibraheem; Elmouna, Ahmed; Jerjees, Dena; Ali, Simak;Buluwela, Laki; Diez-Rodriguez, Maria; Caldas, Carlos; Green, Andrew R; Ellis, Ian O; Rakha, Emad A.
Breast Cancer Res Treat; 159(2): 215-27, 2016 Sep.
26.
St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.
Focke, Cornelia M; van Diest, Paul J; Decker, Thomas.
Breast Cancer Res Treat; 159(2): 257-63, 2016 Sep.
27.
Validated biomarkers: The key to precision treatment in patients with breast cancer.
Duffy, Michael J; O'Donovan, Norma; McDermott, Enda; Crown, John.
Breast; 29: 192-201, 2016 Oct.
28.
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Denkert, Carsten; Wienert, Stephan; Poterie, Audrey; Loibl, Sibylle; Budczies, Jan; Badve, Sunil; Bago-Horvath, Zsuzsanna; Bane, Anita; Bedri, Shahinaz; Brock, Jane; Chmielik, Ewa; Christgen, Matthias; Colpaert, Cecile; Demaria, Sandra; Van den Eynden, Gert; Floris, Giuseppe; Fox, Stephen B; Gao, Dongxia; Ingold Heppner, Barbara; Kim, S Rim;Kos, Zuzana; Kreipe, Hans H; Lakhani, Sunil R; Penault-Llorca, Frederique; Pruneri, Giancarlo; Radosevic-Robin, Nina;Rimm, David L; Schnitt, Stuart J; Sinn, Bruno V; Sinn, Peter; Sirtaine, Nicolas; O'Toole, Sandra A; Viale, Giuseppe; Van de Vijver, Koen; de Wind, Roland; von Minckwitz, Gunter; Klauschen, Frederick; Untch, Michael; Fasching, Peter A; Reimer, Toralf; Willard-Gallo, Karen; Michiels, Stefan; Loi, Sherene; Salgado, Roberto.
Mod Pathol; 29(10): 1155-64, 2016 Oct.
29.
Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients.
Collina, Francesca; Cerrone, Margherita; Peluso, Valentina; Laurentiis, Michelino De; Caputo, Roberta; Cecio, Rossella De; Liguori, Giuseppina; Botti, Gerardo; Cantile, Monica; Bonito, Maurizio Di.
Am J Transl Res; 8(8): 3530-9, 2016.
30.
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park, Chansub; Park, Kyeongmee; Kim, Jiyoung; Sin, Youngjoo; Park, Inseok; Cho, Hyunjin; Yang, Keunho; Bae, Byung Noe; Kim, Ki Whan; Ahn, Sookyung; Gwak, Geumhee.
World J Surg Oncol; 14(1): 244, 2016.
31.
Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Wang, Wei; Wu, Jiayi; Zhang, Peifeng; Fei, Xiaochun; Zong, Yu; Chen, Xiaosong; Huang, Ou; He, Jian-Rong; Chen, Weiguo; Li, Yafen; Shen, Kunwei; Zhu, Li.
Oncotarget; 7(21): 31079-87, 2016 May 24.
32.
Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes, Raquel A; Wray, Lynette; Mete, Mihriye; Herbolsheimer, Pia; Smith, Karen L; Bijelic, Lana; Boisvert, Marc E; Swain, Sandra M.
Breast Cancer Res Treat; 159(3): 481-8, 2016 Oct.
33.
Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López, M E; García-Gómez, J; Alves, M T; Paradela, A; García-Mata, J; García-Caballero, T.
Clin Transl Oncol; 18(10): 996-1002, 2016 Oct.
34.
Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer.
Suman, Shankar; Basak, Trayambak; Gupta, Prachi; Mishra, Sanjay; Kumar, Vijay; Sengupta, Shantanu; Shukla, Yogeshwer.
J Proteomics; 148: 183-93, 2016 Oct 4.
35.
Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients.
Zhou, Meng; Zhong, Lei; Xu, Wanying; Sun, Yifan; Zhang, Zhaoyue; Zhao, Hengqiang; Yang, Lei; Sun, Jie.
Sci Rep; 6: 31038, 2016.
36.
Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer.
Maeda, Ichiro; Abe, Kayoko; Koizumi, Hirotaka; Nakajima, Chika; Tajima, Shinya; Aoki, Hiromi; Tsuchiya, Junichi;Tsuchiya, Seiko; Tsuchiya, Kyoko; Shimo, Arata; Tsugawa, Koichiro; Ueno, Takahiko; Tatsunami, Shinobu; Takagi, Masayuki.
Breast Cancer; 23(5): 745-51, 2016 Sep.
37.
New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer.
Jin, Min-Sun; Park, In Ae; Kim, Ji Young; Chung, Yul Ri; Im, Seock-Ah; Lee, Kyung-Hun; Moon, Hyeong-Gon; Han, Wonshik; Noh, Dong-Young; Ryu, Han Suk.
Tumour Biol; 37(8): 11017-24, 2016 Aug.
38.
Affluence and Breast Cancer.
Lehrer, Steven; Green, Sheryl; Rosenzweig, Kenneth E.
Breast J; 22(5): 564-7, 2016 Sep.
39.
Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer.
Deligonul, Adem; Evrensel, Turkkan; Avci, Nilufer; Ugras, Nesrin; Ture, Mehmet; Cubukcu, Erdem; Hartavi, Mustafa; Fatih Olmez, Omer; Kurt, Ender; Tolunay, Sahsine; Kanat, Ozkan; Manavoglu, Osman.
J BUON; 21(3): 564-9, 2016 May-Jun.
40.
Circulating Tumor Cells in Breast Cancer Patients.
Hall, Carolyn; Valad, Lily; Lucci, Anthony.
Crit Rev Oncog; 21(1-2): 125-39, 2016.
41.
Prognostic value of microRNA-203a expression in breast cancer.
Gomes, Bruno Costa; Martins, Manuela; Lopes, Paulina; Morujão, Inês; Oliveira, Mário; Araújo, António; Rueff, José;Rodrigues, António Sebastião.
Oncol Rep; 36(3): 1748-56, 2016 Sep.
42.
uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Huber, Michaela C; Mall, Rebecca; Braselmann, Herbert; Feuchtinger, Annette; Molatore, Sara; Lindner, Katrin; Walch, Axel; Gross, Eva; Schmitt, Manfred; Falkenberg, Natalie; Aubele, Michaela.
BMC Cancer; 16: 615, 2016.
43.
The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?
Sun, Yadong; Liu, Xiaofeng; Cui, Shude; Li, Lianfang; Tian, Peiqi; Liu, Shanqing; Li, Yong; Yin, Mengmeng; Zhang, Chongjian; Mao, Qixin; Wang, Jiaxiang.
Tumour Biol; 37(7): 9555-63, 2016 Jul.
44.
Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer: A Cohort Study Emphasizing Equivocal Cases.
Shao, Tiffany; Wood, Martha; Wing, Anthony; Hnatovska, Marta; Mendes, Maria; Brendan Mullen, J; Chang, Martin C.
Am J Clin Pathol; 146(3): 339-45, 2016 Sep.
45.
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.
Guerra, Emanuela; Cimadamore, Alessia; Simeone, Pasquale; Vacca, Giovanna; Lattanzio, Rossano; Botti, Gerardo;Gatta, Valentina; D'Aurora, Marco; Simionati, Barbara; Piantelli, Mauro; Alberti, Saverio.
BMC Cancer; 16: 649, 2016.
46.
Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets.
Schindlbeck, C; Andergassen, U; Jueckstock, J; Rack, B; Janni, W; Jeschke, U.
J Cancer Res Clin Oncol; 142(9): 1883-95, 2016 Sep.
47.
Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.
Green, Andrew R; Soria, Daniele; Stephen, Jacqueline; Powe, Desmond G; Nolan, Christopher C; Kunkler, Ian; Thomas, Jeremy; Kerr, Gillian R; Jack, Wilma; Cameron, David; Piper, Tammy; Ball, Graham R; Garibaldi, Jonathan M; Rakha, Emad A; Bartlett, John Ms; Ellis, Ian O.
J Pathol Clin Res; 2(1): 32-40, 2016 Jan.
48.
Prognostic significance of inflammatory factors expression by stroma from breast carcinomas.
Fernandez-Garcia, Belen; Eiro, Noemi; Miranda, Maria-Angeles; Cid, Sandra; González, Luis O; Domínguez, Francisco;Vizoso, Francisco J.
Carcinogenesis; 37(8): 768-76, 2016 Aug.
49.
Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
Shiino, Sho; Kinoshita, Takayuki; Yoshida, Masayuki; Jimbo, Kenjiro; Asaga, Sota; Takayama, Shin; Tsuda, Hitoshi.
Clin Breast Cancer; 16(4): e133-40, 2016 Aug.
50.
New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.
Hao, Shuang; He, Zhi-Xian; Yu, Ke-Da; Yang, Wen-Tao; Shao, Zhi-Min.
Oncotarget; 7(17): 24824-31, 2016 Apr 26.
51.
PD-L1 expression in human cancers and its association with clinical outcomes.
Wang, Xin; Teng, Feifei; Kong, Li; Yu, Jinming.
Onco Targets Ther; 9: 5023-39, 2016.
52.
Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about "Triple-negative breast cancer: treatment challenges and solutions" by Collignon et al.
Ieni, Antonio; Barresi, Valeria; Ricciardi, Giuseppina Rosaria Rita; Adamo, Barbara; Adamo, Vincenzo; Tuccari, Giovanni.
Breast Cancer (Dove Med Press); 8: 157-9, 2016.
53.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Gluz, Oleg; Nitz, Ulrike A; Christgen, Matthias; Kates, Ronald E; Shak, Steven; Clemens, Michael; Kraemer, Stefan; Aktas, Bahriye; Kuemmel, Sherko; Reimer, Toralf; Kusche, Manfred; Heyl, Volker; Lorenz-Salehi, Fatemeh; Just, Marianne;Hofmann, Daniel; Degenhardt, Tom; Liedtke, Cornelia; Svedman, Christer; Wuerstlein, Rachel; Kreipe, Hans H; Harbeck, Nadia.
J Clin Oncol; 34(20): 2341-9, 2016 Jul 10.
54.
Prognostic factor analysis for breast cancer using gene expression profiles.
Joe, Soobok; Nam, Hojung.
BMC Med Inform Decis Mak; 16 Suppl 1: 56, 2016.
55.
The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer.
Ordu, Cetin; McGuire, Kandace; Alco, Gul; Nur Pilanci, Kezban; Koksal, Ulkuhan I; Elbüken, Filiz; Erdogan, Zeynep;Agacayak, Filiz; Ilgun, Serkan; Sarsenov, Dauren; Öztürk, Alper; Igdem, Sefik; Okkan, Sait; Eralp, Yesim; Dincer, Maktav;Ozmen, Vahit.
Cureus; 8(6): e633, 2016.
56.
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock, Julia; Rack, Brigitte; Friedl, Thomas W P; Scholz, Christoph; Steidl, Julia; Trapp, Elisabeth; Tesch, Hans;Forstbauer, Helmut; Lorenz, Ralf; Rezai, Mahdi; Häberle, Lothar; Alunni-Fabbroni, Marianna; Schneeweiss, Andreas;Beckmann, Matthias W; Lichtenegger, Werner; Fasching, Peter A; Pantel, Klaus; Janni, Wolfgang.
BMC Cancer; 16: 401, 2016.
57.
Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely, Dvir; Avraham, Ayelet; Ben-Baruch, Adit; Evron, Ella; Shamir, Ron.
Breast Cancer Res; 18(1): 74, 2016.
58.
Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson, Sara; Bendahl, Pär-Ola; Larsson, Anna-Maria; Aaltonen, Kristina E; Rydén, Lisa.
BMC Cancer; 16: 433, 2016.
59.
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis.
Nottegar, A; Veronese, N; Senthil, M; Roumen, R M; Stubbs, B; Choi, A H; Verheuvel, N C; Solmi, M; Pea, A; Capelli, P;Fassan, M; Sergi, G; Manzato, E; Maruzzo, M; Bagante, F; Koç, M; Eryilmaz, M A; Bria, E; Carbognin, L; Bonetti, F;Barbareschi, M; Luchini, C.
Eur J Surg Oncol; 42(7): 919-25, 2016 Jul.
60.
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
Dai, Xiaofeng; Xiang, Liangjian; Li, Ting; Bai, Zhonghu.
J Cancer; 7(10): 1281-94, 2016.
61.
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
Guo, Lei; Li, Wenbin; Zhu, Xinxin; Ling, Yun; Qiu, Tian; Dong, Lin; Fang, Yi; Yang, Hongying; Ying, Jianming.
Springerplus; 5(1): 805, 2016.
62.
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida, Akira I; Sagara, Yasuaki; Yotsumoto, Daisuke; Kanemitsu, Shuichi; Kawano, Junko; Baba, Shinichi; Rai, Yoshiaki;Oshiro, Yumi; Aogi, Kenjiro; Sagara, Yoshiaki; Ohi, Yasuyo.
Breast Cancer Res Treat; 158(1): 1-9, 2016 Jul.
63.
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
Kurozumi, Sasagu; Padilla, Mary; Kurosumi, Masafumi; Matsumoto, Hiroshi; Inoue, Kenichi; Horiguchi, Jun; Takeyoshi, Izumi; Oyama, Tetsunari; Ranger-Moore, Jim; Allred, D Craig; Dennis, Eslie; Nitta, Hiroaki.
Breast Cancer Res Treat; 158(1): 99-111, 2016 Jul.
64.
Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer.
Juríková, Miroslava; Danihel, Ludovít; Polák, Stefan; Varga, Ivan.
Acta Histochem; 118(5): 544-52, 2016 Jun.
65.
Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy.
Wen, Ge; Zhang, Jin-Shan; Zhang, Yu-Jing; Zhu, Yu-Jia; Huang, Xiao-Bo; Guan, Xun-Xing.
J Breast Cancer; 19(2): 176-84, 2016 Jun.
66.
Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
Grosset, Andrée-Anne; Labrie, Marilyne; Vladoiu, Maria Claudia; Yousef, Einas M; Gaboury, Louis; St-Pierre, Yves.
Oncotarget; 7(14): 18183-203, 2016 Apr 5.
67.
HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker, Albina; Hilbers, Marie-Luise; Gauthier, Claire; Grogg, Josias; Kullak-Ublick, Gerd A; Seifert, Burkhardt; Varga, Zsuzsanna; Trojan, Andreas.
PLoS One; 11(7): e0159176, 2016.
68.
The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Cockburn, Jessica G; Hallett, Robin M; Gillgrass, Amy E; Dias, Kay N; Whelan, T; Levine, M N; Hassell, John A; Bane, Anita.
BMC Cancer; 16: 555, 2016.
69.
Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.
Wang, Ruo-Xi; Chen, Sheng; Jin, Xi; Shao, Zhi-Ming.
Sci Rep; 6: 30091, 2016.
70.
Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
Bendrat, Klaus; Fritz, Peter; Müller, Simon; Brockmöller, Sylvia; Debus, Annegret; Friedrichs, Kay; Lindner, Christoph;Brinkmann, Friedhelm; Heidemann, Else; Niendorf, Axel.
Anticancer Res; 36(8): 3855-63, 2016 Aug.
71.
Immunotherapy in Breast Cancer.
Marmé, Frederik.
Oncol Res Treat; 39(6): 335-45, 2016.
72.
Prognostic Factors for Breast Cancer: an Immunomorphological Update.
Roncati, Luca; Barbolini, Giuseppe; Piacentini, Federico; Piscioli, Francesco; Pusiol, Teresa; Maiorana, Antonio.
Pathol Oncol Res; 22(3): 449-52, 2016 Jul.
73.
Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao, Lin; Niu, Fengting; Shen, Honghong; Liu, Xiaozhen; Chen, Lijuan; Niu, Yun.
Virchows Arch; 468(6): 687-96, 2016 Jun.
74.
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Wirtz, Ralph M; Sihto, Harri; Isola, Jorma; Heikkilä, Päivi; Kellokumpu-Lehtinen, Pirkko-Liisa; Auvinen, Päivi;Turpeenniemi-Hujanen, Taina; Jyrkkiö, Sirkku; Lakis, Sotiris; Schlombs, Kornelia; Laible, Mark; Weber, Stefan; Eidt, Sebastian; Sahin, Ugur; Joensuu, Heikki.
Breast Cancer Res Treat; 157(3): 437-46, 2016 Jun.
75.
The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice.
Bao, Jean; Donovan, Cory; Chung, Alice; Giuliano, Armando E.
Chin Clin Oncol; 5(3): 36, 2016 Jun.
76.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein, R; Sotlar, K; Gluz, O; Otremba, B; von Schumann, R; Witzel, I; Schindlbeck, C; Janni, W; Schem, C;Bauerfeind, I; Hasmueller, S; Tesch, H; Paulenz, A; Ghali, N; Orujov, E; Kates, R E; Cowens, W; Hornberger, J; Pelz, E;Harbeck, N.
Curr Med Res Opin; 32(7): 1217-24, 2016 Jul.
77.
Significance of prognostic indicators in infiltrating duct carcinoma breast: Scenario in developing country.
Krishnamurthy, J; Kumar, P Sandeep.
Indian J Cancer; 53(1): 34-8, 2016 Jan-Mar.
78.
Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.
Schmidt, Gilda; Gerlinger, Christoph; Juhasz-Böss, Ingolf; Stickeler, Elmar; Rody, Achim; Liedtke, Cornelia; Wimberger, Pauline; Link, Theresa; Müller, Eberhard; Fehm, Tanja; Abel, Manuela; Stein, Stefan; Bohle, Rainer; Endrikat, Jan;Solomayer, Erich-Franz.
J Cancer Res Clin Oncol; 142(6): 1369-76, 2016 Jun.
79.
New Gene Profiling in Determination of Breast Cancer Recurrence and Prognosis in Iranian Women.
Poorhosseini, Seyed Mohammad; Hashemi, Mohammad; Alipour Olyaei, Nasrin; Izadi, Amir; Moslemi, Elham; Ravesh, Zeinab; Hashemi-Gorji, Feyzollah; Kheiri, Hamid Reza; Yassaee, Vahid Reza.
Asian Pac J Cancer Prev; 17 Spec No.: 155-60, 2016.
80.
The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients.
Madani, Seyed-Hamid; Payandeh, Mehrdad; Sadeghi, Masoud; Motamed, Hajar; Sadeghi, Edris.
Indian J Med Paediatr Oncol; 37(2): 95-9, 2016 Apr-Jun.
81.
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
Tobin, Nicholas P; Wennmalm, Kristian; Lindström, Linda S; Foukakis, Theodoros; He, Liqun; Genové, Guillem; Östman, Arne; Landberg, Göran; Betsholtz, Christer; Bergh, Jonas.
Clin Cancer Res; 22(10): 2417-26, 2016 May 15.
82.
Determining breast cancer histological grade from RNA-sequencing data.
Wang, Mei; Klevebring, Daniel; Lindberg, Johan; Czene, Kamila; Grönberg, Henrik; Rantalainen, Mattias.
Breast Cancer Res; 18(1): 48, 2016.
83.
Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi, Ahoua B; Aman, N'guiessan A; Koui, Baumaney S; Koffi, Kouadio D; Traore, Zie C; Kouyate, Mohamed.
Asian Pac J Cancer Prev; 17(4): 1973-8, 2016.
84.
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Desmedt, Christine; Zoppoli, Gabriele; Gundem, Gunes; Pruneri, Giancarlo; Larsimont, Denis; Fornili, Marco; Fumagalli, Debora; Brown, David; Rothé, Françoise; Vincent, Delphine; Kheddoumi, Naima; Rouas, Ghizlane; Majjaj, Samira;Brohée, Sylvain; Van Loo, Peter; Maisonneuve, Patrick; Salgado, Roberto; Van Brussel, Thomas; Lambrechts, Diether;Bose, Ron; Metzger, Otto; Galant, Christine; Bertucci, François; Piccart-Gebhart, Martine; Viale, Giuseppe; Biganzoli, Elia;Campbell, Peter J; Sotiriou, Christos.
J Clin Oncol; 34(16): 1872-81, 2016 Jun 1.
85.
New Strategies in Breast Cancer: Immunotherapy.
Pusztai, Lajos; Karn, Thomas; Safonov, Anton; Abu-Khalaf, Maysa M; Bianchini, Giampaolo.
Clin Cancer Res; 22(9): 2105-10, 2016 May 1.
86.
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer.
Ingold Heppner, Barbara; Loibl, Sibylle; Denkert, Carsten.
Breast Care (Basel); 11(2): 96-100, 2016 Apr.
87.
Prognostic impact of breast cancer subtypes in elderly patients.
Bergen, E S; Tichy, C; Berghoff, A S; Rudas, M; Dubsky, P; Bago-Horvath, Z; Mader, R M; Exner, R; Gnant, M; Zielinski, C C; Steger, G G; Preusser, M; Bartsch, R.
Breast Cancer Res Treat; 157(1): 91-9, 2016 May.
88.
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
Bustreo, Sara; Osella-Abate, Simona; Cassoni, Paola; Donadio, Michela; Airoldi, Mario; Pedani, Fulvia; Papotti, Mauro;Sapino, Anna; Castellano, Isabella.
Breast Cancer Res Treat; 157(2): 363-71, 2016 Jun.
89.
Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
Kasimir-Bauer, Sabine; Reiter, Katharina; Aktas, Bahriye; Bittner, Ann-Kathrin; Weber, Stephan; Keller, Thomas; Kimmig, Rainer; Hoffmann, Oliver.
Sci Rep; 6: 26355, 2016.
90.
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
Green, Andrew R; Soria, D; Powe, D G; Nolan, C C; Aleskandarany, M; Szász, M A; Tokés, A M; Ball, G R; Garibaldi, J M;Rakha, E A; Kulka, J; Ellis, I O.
Breast Cancer Res Treat; 157(1): 65-75, 2016 May.
91.
Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.
Bonneterre, Jacques; Prat, Aleix; Galván, Patricia; Morel, Pascale; Giard, Sylvia.
Curr Med Res Opin; 32(5): 835-9, 2016 May.
92.
A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma.
Cimino-Mathews, Ashley; Verma, Sangita; Figueroa-Magalhaes, Maria Cristina; Jeter, Stacie C; Zhang, Zhe; Argani, Pedram; Stearns, Vered; Connolly, Roisin M.
Am J Clin Pathol; 145(3): 365-72, 2016 Mar.
93.
Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.
Lakis, Sotirios; Dimoudis, Stefanos; Kotoula, Vassiliki; Alexopoulou, Zoi; Kostopoulos, Ioannis; Koletsa, Triantafyllia;Bobos, Mattheos; Timotheadou, Eleni; Papaspirou, Irene; Efstratiou, Ioannis; Aravantinos, Gerasimos; Karavasilis, Vasilios; Zagouri, Flora; Gogas, Helen; Razis, Evangelia; Pentheroudakis, George; Christodoulou, Christos; Pectasides, Dimitrios; Fountzilas, George.
Anticancer Res; 36(5): 2365-78, 2016 May.
94.
Prognostic significance of Nottingham Prognostic Index in non-metastatic breast cancer.
Benderli Cihan, Yasemin; Sarigoz, Talha.
J BUON; 21(1): 279, 2016 Jan-Feb.
95.
Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh, Mehrdad; Shahriari-Ahmadi, Ali; Sadeghi, Masoud; Sadeghi, Edris.
Asian Pac J Cancer Prev; 17(3): 1015-8, 2016.
96.
Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz, Fatemeh Homaei; Shabahang, Hossein; Afzaljavan, Fahimeh; Sharifi, Nourieh; Tavasoli, Alireza; Afzalaghaee, Monavar; Roshanzamir, Emane; Pasdar, Alireza.
Asian Pac J Cancer Prev; 17(3): 1347-50, 2016.
97.
Highlights of the San Antonio Breast Cancer Symposium 2015: part 1.
Benson, John R; Jatoi, Ismail.
Future Oncol; 12(7): 893-6, 2016 Apr.
98.
Highlights of the San Antonio Breast Cancer Symposium 2015: part 2.
Benson, John R; Jatoi, Ismail.
Future Oncol; 12(7): 897-900, 2016 Apr.
99.
Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy.
Tallet, Agnès; Lambaudie, Eric; Cohen, Monique; Minsat, Mathieu; Bannier, Marie; Resbeut, Michel; Houvenaeghel, Gilles.
World J Clin Oncol; 7(2): 243-52, 2016 Apr 10.
100.
Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis.
Tan, Weige; Li, Qian; Chen, Kai; Su, Fengxi; Song, Erwei; Gong, Chang.
Oncotarget; 7(9): 10373-85, 2016 Mar 1.
101.
Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.
Gheybi, Mohammad Kazzem; Baradaran, Azar; Mohajeri, Mohammad Reza; Ostovar, Afshin; Hajalikhani, Parvaneh;Farrokhi, Shokrollah.
APMIS; 124(5): 365-71, 2016 May.
102.
Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius, Arvydas; Plancoulaine, Benoit; Rasmusson, Allan; Besusparis, Justinas; Augulis, Renaldas; Meskauskas, Raimundas; Herlin, Paulette; Laurinaviciene, Aida; Abdelhadi Muftah, Abir A; Miligy, Islam; Aleskandarany, Mohammed;Rakha, Emad A; Green, Andrew R; Ellis, Ian O.
Virchows Arch; 468(4): 493-502, 2016 Apr.
103.
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah, Payal D; Patil, Sujata; Dickler, Maura N; Offit, Kenneth; Hudis, Clifford A; Robson, Mark E.
Cancer; 122(8): 1178-84, 2016 Apr 15.
104.
Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.
Yu, X; Zhang, Z; Wang, Z; Wu, P; Qiu, F; Huang, J.
Clin Transl Oncol; 18(5): 497-506, 2016 May.
105.
Human mammaglobin: A specific marker for breast cancer prognosis.
Li, Chuanying; Zhang, Tingguo.
J BUON; 21(1): 35-41, 2016 Jan-Feb.
106.
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato, Claudette; Tobin, Nicholas P; Lorent, Julie; Lindström, Linda S; Bergh, Jonas; Foukakis, Theodoros.
Mol Oncol; 10(4): 517-25, 2016 Apr.
107.
The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis.
Engels, Charla C; Kiderlen, Mandy; Bastiaannet, Esther; Mooyaart, Antien L; van Vlierberghe, Ronald; Smit, Vincent T H B M; Kuppen, Peter J K; van de Velde, Cornelis J H; Liefers, G J.
Mol Oncol; 10(4): 594-600, 2016 Apr.
108.
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.
Mao, Yan; Qu, Qing; Chen, Xiaosong; Huang, Ou; Wu, Jiayi; Shen, Kunwei.
PLoS One; 11(4): e0152500, 2016.
109.
Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato, Kaolu; Miyashita, Minoru; Ishida, Takanori; Suzuki, Akihiko; Tada, Hiroshi; Watanabe, Go; Sato-Tadano, Akiko;Watanabe, Mika; Ohuchi, Noriaki.
Breast Cancer; 23(2): 310-7, 2016 Mar.
110.
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
Falck, A K; Röme, A; Fernö, M; Olsson, H; Chebil, G; Bendahl, P O; Rydén, L.
Br J Surg; 103(5): 513-23, 2016 Apr.
111.
Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers.
Kim, Hyung Sun; Park, Seho; Koo, Ja Seung; Kim, Sanghwa; Kim, Jee Ye; Nam, Sanggeun; Park, Hyung Seok; Kim, Seung Il; Park, Byeong-Woo.
PLoS One; 11(3): e0151054, 2016.
112.
Impact of estrogen receptor-ß expression on breast cancer prognosis: a meta-analysis.
Liu, Jieqiong; Guo, Huishan; Mao, Kai; Zhang, Kan; Deng, Heran; Liu, Qiang.
Breast Cancer Res Treat; 156(1): 149-62, 2016 Feb.
113.
Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score.
Hartkopf, Andreas D; Wallwiener, Markus; Kommoss, Stefan; Taran, Florin-Andrei; Brucker, Sara Y.
Breast Cancer Res Treat; 156(1): 91-5, 2016 Feb.
114.
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin, Luisa; Pilotto, Sara; Nortilli, Rolando; Brunelli, Matteo; Nottegar, Alessia; Sperduti, Isabella; Giannarelli, Diana;Bria, Emilio; Tortora, Giampaolo.
Oncologist; 21(3): 283-91, 2016 Mar.
115.
Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi, Yayoi; Ishiguro, Junko; Kotani, Haruru; Hisada, Tomoka; Ichikawa, Mari; Gondo, Naomi; Yoshimura, Akiyo; Kondo, Naoto; Hattori, Masaya; Sawaki, Masataka; Fujita, Takashi; Kikumori, Toyone; Yatabe, Yasushi; Kodera, Yasuhiro; Iwata, Hiroji.
BMC Cancer; 16: 248, 2016.
116.
Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto, Takayuki; Kelly, Catherine; Mizoo, Taeko; Nogami, Tomohiro; Motoki, Takayuki; Shien, Tadahiko; Taira, Naruto;Hayashi, Naoki; Niikura, Naoki; Fujiwara, Toshiyoshi; Doihara, Hiroyoshi; Matsuoka, Junji.
Clin Breast Cancer; 16(2): 95-100.e1, 2016 Apr.
117.
Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
Boudin, Laurys; Chabannon, Christian; Sfumato, Patrick; Sabatier, Renaud; Bertucci, François; Tarpin, Carole; Provansal, Magali; Houvenaegel, Gilles; Lambaudie, Eric; Tallet, Agnes; Resbeut, Michel; Charafe-Jauffret, Emmanuelle; Calmels, Boris; Lemarie, Claude; Boher, Jean-Marie; Extra, Jean-Marc; Viens, Patrice; Gonçalves, Anthony.
Eur J Cancer; 57: 118-26, 2016 Apr.
118.
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma, Cynthia X; Bose, Ron; Ellis, Matthew J.
Adv Exp Med Biol; 882: 125-54, 2016.
119.
Circulating Tumor Cells.
Paoletti, Costanza; Hayes, Daniel F.
Adv Exp Med Biol; 882: 235-58, 2016.
120.
Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda, Tetsuyo; Nakanishi, Yoko; Hirotani, Yukari; Fuchinoue, Fumi; Enomoto, Katsuhisa; Sakurai, Kenichi; Amano, Sadao; Nemoto, Norimichi.
Med Mol Morphol; 49(1): 11-21, 2016 Mar.
121.
Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb, Christopher S; Jani, Ashish; Wu, Cheng-Chia; Saad, Shumaila; Qureshi, Yasir H; Nanda, Tavish; Yaeh, Andrew;Rozenblat, Tzlil; Sisti, Michael B; Bruce, Jeffrey N; McKhann, Guy M; Sheth, Sameer A; Lesser, Jeraldine; Cheng, Simon K; Isaacson, Steven R; Lassman, Andrew B; Connolly, Eileen P; Wang, Tony J C.
J Neurooncol; 127(1): 103-10, 2016 Mar.
122.
Factores pronósticos en el cáncer de mama en estadio inicial. / [Prognostic factors of early breast cancer].
Almagro, Elena; González, Cynthia S; Espinosa, Enrique.
Med Clin (Barc); 146(4): 167-71, 2016 Feb 19.
123.
Bone marrow micrometastases in early breast cancer-30-year outcome.
Mansi, J; Morden, J; Bliss, J M; Neville, M; Coombes, R C.
Br J Cancer; 114(3): 243-7, 2016 Feb 2.
124.
Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis.
Lv, Q; Gong, L; Zhang, T; Ye, J; Chai, L; Ni, C; Mao, Y.
Clin Transl Oncol; 18(3): 322-30, 2016 Mar.
125.
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis, Michail; Azim, Hatem A; Desmedt, Christine; Veys, Isabelle; Larsimont, Denis; Salgado, Roberto; Lyng, Maria B;Viale, Giuseppe; Leyland-Jones, Brian; Giobbie-Hurder, Anita; Kammler, Rosita; Dell'Orto, Patrizia; Rothé, Françoise;Laïos, Ioanna; Ditzel, Henrik J; Regan, Meredith M; Piccart, Martine; Michiels, Stefan; Sotiriou, Christos.
JAMA Oncol; 2(2): 217-24, 2016 Feb.
126.
Circulating tumor cells in breast cancer.
Bidard, Francois-Clement; Proudhon, Charlotte; Pierga, Jean-Yves.
Mol Oncol; 10(3): 418-30, 2016 Mar.
127.
The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer.
Wang, Dexing; Duan, Li; Tu, Zhiquan; Yan, Fei; Zhang, Cuicui; Li, Xu; Cao, Yuzhu; Wen, Hongsheng.
Chemotherapy; 61(4): 217-22, 2016.
128.
Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy, Mohamed A; Albasri, Abdulkader M; Mohammed, Rabab A; Hussainy, Akbar S; Nouh, Magdy M; Alhujaily, Ahmed S.
Saudi Med J; 37(2): 137-41, 2016 Feb.
129.
HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah, Tarek M A; McArdle, Stephanie E B; Agarwal, Devika; Moseley, Paul M; Green, Andrew R; Ball, Graham R;Pockley, A Graham; Ellis, Ian O; Rees, Robert C; Chan, Stephen Y T.
Clin Cancer Res; 22(4): 905-14, 2016 Feb 15.
130.
Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
Laas, Enora; Mallon, Peter; Duhoux, Francois P; Hamidouche, Amina; Rouzier, Roman; Reyal, Fabien.
PLoS One; 11(2): e0148957, 2016.
131.
Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
Galimberti, V; Ribeiro Fontana, S K; Maisonneuve, P; Steccanella, F; Vento, A R; Intra, M; Naninato, P; Caldarella, P;Iorfida, M; Colleoni, M; Viale, G; Grana, C M; Rotmensz, N; Luini, A.
Eur J Surg Oncol; 42(3): 361-8, 2016 Mar.
132.
Circulating tumor cells in breast cancer--current status and perspectives.
Banys-Paluchowski, Malgorzata; Krawczyk, Natalia; Meier-Stiegen, Franziska; Fehm, Tanja.
Crit Rev Oncol Hematol; 97: 22-9, 2016 Jan.
133.
Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients.
Hartkopf, Andreas D; Wallwiener, Markus; Hahn, Markus; Fehm, Tanja N; Brucker, Sara Y; Taran, Florin-Andrei.
Cancer Res Treat; 48(1): 115-24, 2016 Jan.
134.
Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma.
Kim, Hyosun; Cho, Jihyoung; Kwon, Sun Young; Kang, Sun Hee.
Ann Surg Treat Res; 90(1): 1-9, 2016 Jan.
135.
Circulating tumor cells in breast cancer patients.
Bystricky, B; Mego, M.
Neoplasma; 63(1): 18-29, 2016.
136.
Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy.
Ren, Chuanli; Han, Chongxu; Fu, Deyuan; Wang, Daxin; Chen, Hui; Chen, Yong; Shen, Ming.
Int J Cancer; 138(7): 1586-600, 2016 Apr 1.
137.
Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian, Stacey K; Bombonati, Alessandro; Palazzo, Juan P.
Hum Pathol; 49: 114-23, 2016 Mar.
138.
Biological markers of invasive breast cancer.
Matsumoto, Akiko; Jinno, Hiromitsu; Ando, Tomofumi; Fujii, Taku; Nakamura, Tetsuya; Saito, Junichi; Takahashi, Maiko;Hayashida, Tetsu; Kitagawa, Yuko.
Jpn J Clin Oncol; 46(2): 99-105, 2016 Feb.
139.
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido, Paula; Cabal, María Luque; Fernández, Ignacio Peláez; Pérez, Yolanda Fernández.
Clin Med Insights Oncol; 10(Suppl 1): 31-9, 2016.
140.
Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis.
Wang, Zhu; Wang, Qianqian; Wang, Qi; Wang, Yanping; Chen, Jie.
Int J Biol Markers; : 0, 2016 Jul 27.
141.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri, Giancarlo; Gray, Kathryn P; Vingiani, Andrea; Viale, Giuseppe; Curigliano, Giuseppe; Criscitiello, Carmen; Láng, István; Ruhstaller, Thomas; Gianni, Lorenzo; Goldhirsch, Aron; Kammler, Roswitha; Price, Karen N; Cancello, Giuseppe;Munzone, Elisabetta; Gelber, Richard D; Regan, Meredith M; Colleoni, Marco.
Breast Cancer Res Treat; 158(2): 323-31, 2016 Jul.
142.
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
Iglesia, Michael D; Parker, Joel S; Hoadley, Katherine A; Serody, Jonathan S; Perou, Charles M; Vincent, Benjamin G.
J Natl Cancer Inst; 108(11)2016 Nov.
143.
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Miller, Lance D; Chou, Jeff A; Black, Michael A; Print, Cristin; Chifman, Julia; Alistar, Angela; Putti, Thomas; Zhou, Xiaobo;Bedognetti, Davide; Hendrickx, Wouter; Pullikuth, Ashok; Rennhack, Jonathan; Andrechek, Eran R; Demaria, Sandra;Wang, Ena; Marincola, Francesco M.
Cancer Immunol Res; 4(7): 600-10, 2016 Jul.
144.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
King, Tari A; Lyman, Jaclyn P; Gonen, Mithat; Voci, Amy; De Brot, Marina; Boafo, Camilla; Sing, Amy Pratt; Hwang, E Shelley; Alvarado, Michael D; Liu, Minetta C; Boughey, Judy C; McGuire, Kandace P; Van Poznak, Catherine H; Jacobs, Lisa K; Meszoely, Ingrid M; Krontiras, Helen; Babiera, Gildy V; Norton, Larry; Morrow, Monica; Hudis, Clifford A.
J Clin Oncol; 34(20): 2359-65, 2016 Jul 10.
145.
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita, Hiroko; Ogiya, Akiko; Shien, Tadahiko; Horimoto, Yoshiya; Masuda, Norikazu; Inao, Touko; Osako, Tomofumi;Takahashi, Masato; Endo, Yumi; Hosoda, Mitsuchika; Ishida, Naoko; Horii, Rie; Yamazaki, Kieko; Miyoshi, Yuichiro;Yasojima, Hiroyuki; Tomioka, Nobumoto.
Breast Cancer; 23(6): 830-843, 2016 Nov.
146.
The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis.
Lu, Yan-Jun; Wang, Peng; Wang, Xiong; Peng, Jing; Zhu, Yao-Wu; Shen, Na.
Oncotarget; 7(24): 37361-37369, 2016 Jun 14.
147.
Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.
Sawada, Takeshi; Araki, Jungo; Yamashita, Toshinari; Masubuchi, Manami; Chiyoda, Tsuneko; Yunokawa, Mayu; Hoshi, Kumiko; Tao, Shoichi; Yamamura, Shohei; Yatsushiro, Shouki; Abe, Kaori; Kataoka, Masatoshi; Shimoyama, Tatsu;Maeda, Yoshiharu; Kuroi, Katsumasa; Tamura, Kenji; Sawazumi, Tsuneo; Minami, Hironobu; Suda, Yoshihiko; Koizumi, Fumiaki.
EBioMedicine; 11: 173-182, 2016 Sep.
148.
Multi-gene classifiers for prediction of recurrence in breast cancer patients.
Naoi, Yasuto; Noguchi, Shinzaburo.
Breast Cancer; 23(1): 12-8, 2016 Jan.
149.
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa, Takahiro; Fouad, Tamer M; Liu, Diane D; Wu, Jimin; Shen, Yu; Masuda, Hiroko; Fujii, Takeo; Chavez-MacGregor, Mariana; Alvarez, Ricardo H; Hortobágyi, Gabriel N; Valero, Vicente; Ueno, Naoto T.
Oncologist; 21(1): 21-7, 2016 Jan.
150.
Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.
Braunstein, Lior Z; Taghian, Alphonse G.
Semin Radiat Oncol; 26(1): 9-16, 2016 Jan.
151.
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders, Carey K; Abramson, Vandana; Tan, Tira; Dent, Rebecca.
Am Soc Clin Oncol Educ Book; 35: 34-42, 2016.
152.
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue, Yong; Astvatsaturyan, Kristine; Cui, Xiaojiang; Zhang, Xiao; Fraass, Benedick; Bose, Shikha.
PLoS One; 11(3): e0149661, 2016.
153.
The cancer genetics and pathology of male breast cancer.
Deb, Siddhartha; Lakhani, Sunil R; Ottini, Laura; Fox, Stephen B.
Histopathology; 68(1): 110-8, 2016 Jan.
154.
Signatures of breast cancer metastasis at a glance.
Karagiannis, George S; Goswami, Sumanta; Jones, Joan G; Oktay, Maja H; Condeelis, John S.
J Cell Sci; 129(9): 1751-8, 2016 May 1.
155.
Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients.
Hall, Carolyn S; Karhade, Mandar G; Bowman Bauldry, Jessica B; Valad, Lily M; Kuerer, Henry M; DeSnyder, Sarah M;Lucci, Anthony.
J Am Coll Surg; 223(1): 20-9, 2016 Jul.
156.
Role of the androgen receptor in triple-negative breast cancer.
Rampurwala, Murtuza; Wisinski, Kari B; O'Regan, Ruth.
Clin Adv Hematol Oncol; 14(3): 186-93, 2016 Mar.
157.
Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer.
Becker, Marc A; Ibrahim, Yasir H; Oh, Annabell S; Fagan, Dedra H; Byron, Sara A; Sarver, Aaron L; Lee, Adrian V; Shaw, Leslie M; Fan, Cheng; Perou, Charles M; Yee, Douglas.
PLoS One; 11(3): e0150564, 2016.
158.
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer.
Kim, Ji-Yeon; Park, Kyunghee; Jung, Hae Hyun; Lee, Eunjin; Cho, Eun Yoon; Lee, Kwang Hee; Bae, Soo Youn; Lee, Se Kyung; Kim, Seok Won; Lee, Jeong Eon; Nam, Seok Jin; Ahn, Jin Seok; Im, Young-Hyuck; Park, Yeon Hee.
Cancer Res Treat; 48(4): 1338-1350, 2016 Oct.
159.
Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc; Cimino-Mathews, Ashley; Garay, Joseph P; Fessler, Abigail G;Rasheed, Zeshaan A; Hicks, Jessica; Cochran, Rory L; Croessmann, Sarah; Zabransky, Daniel J; Mohseni, Morassa;Beaver, Julia A; Chu, David; Cravero, Karen; Christenson, Eric S; Medford, Arielle; Mattox, Austin; De Marzo, Angelo M;Argani, Pedram; Chawla, Ajay; Hurley, Paula J; Lauring, Josh; Park, Ben Ho.
Oncotarget; 7(5): 6281-93, 2016 Feb 2.
160.
Prognostic significance of PD-L1 and PD-L2 in breast cancer.
Baptista, Mauricio Z; Sarian, Luis Otavio; Derchain, Sophie F M; Pinto, Glauce A; Vassallo, José.
Hum Pathol; 47(1): 78-84, 2016 Jan.
161.
The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance.
Hou, Shuyun; Sang, Meixiang; Zhao, Lianmei; Hou, Ran; Shan, Baoen.
Am J Surg; 211(1): 142-51, 2016 Jan.
162.
Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
Canevari, Renata A; Marchi, Fabio A; Domingues, Maria A C; de Andrade, Victor Piana; Caldeira, José R F; Verjovski-Almeida, Sergio; Rogatto, Silvia R; Reis, Eduardo M.
Tumour Biol; 2016 Aug 2.
163.
Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Fang, Yan; Wu, Jiayi; Wang, Wei; Fei, Xiaochun; Zong, Yu; Chen, Xiaosong; Huang, Ou; He, Jianrong; Chen, Weiguo; Li, Yafen; Shen, Kunwei; Zhu, Li.
Oncotarget; 2016 Aug 26.
164.
Triple Negative Breast Cancer: A Tale of Two Decades.
Ali, Arwa Mohammed; Ansari, Jawaher Ali; AbdelAziz, Nashwa Mohammed; Aabozeed, Waleed; Warith, Ahmed; Alsaleh, Khalid; Nabholtz, Jean-Marc.
Anticancer Agents Med Chem; 2016 Jul 25.
165.
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono, Makiko; Tsuda, Hitoshi; Yoshida, Masayuki; Shimizu, Chikako; Kinoshita, Takayuki; Tamura, Kenji.
Clin Breast Cancer; 2016 Jun 25.